Trade Report: Today, Valeant Pharmaceuticals International’s (VRX) Neutral Rating Reaffirmed at Mizuho

Today, Valeant Pharmaceuticals International’s (VRX) Neutral Rating Reaffirmed at Mizuho

Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “neutral” rating reiterated by investment analysts at Mizuho in a research report issued on Saturday. They currently have a $25.00 target price on the specialty pharmaceutical company’s stock. Mizuho’s price objective indicates a potential upside of 47.06% from the stock’s current price.

A number of other brokerages also recently issued reports on VRX. Wells Fargo & Co. reiterated an “underperform” rating and issued a $19.50 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, August 10th. Canaccord Genuity restated a “hold” rating and set a $33.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Thursday, November 3rd. Royal Bank Of Canada boosted their price objective on shares of Valeant Pharmaceuticals International from $31.00 to $36.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 10th. Deutsche Bank AG began coverage on shares of Valeant Pharmaceuticals International in a research report on Tuesday, September 20th. They set a “hold” rating and a $30.00 price objective for the company. Finally, TD Securities restated a “buy” rating and set a $38.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Saturday, August 13th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has an average rating of “Hold” and a consensus target price of $39.63.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded up 0.35% during mid-day trading on Friday, reaching $17.00. 8,772,323 shares of the company were exchanged. The stock’s market capitalization is $5.91 billion. Valeant Pharmaceuticals International has a 12 month low of $13.77 and a 12 month high of $119.87. The stock has a 50 day moving average price of $20.02 and a 200-day moving average price of $24.13.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by $0.23. Valeant Pharmaceuticals International had a positive return on equity of 43.81% and a negative net margin of 22.17%. The firm earned $2.48 billion during the quarter, compared to analysts’ expectations of $2.49 billion. During the same quarter in the prior year, the firm earned $2.74 EPS. The firm’s revenue was down 11.0% compared to the same quarter last year. Analysts predict that Valeant Pharmaceuticals International will post $5.43 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Riggs Asset Managment Co. Inc. increased its position in Valeant Pharmaceuticals International by 1.4% in the second quarter. Riggs Asset Managment Co. Inc. now owns 14,044 shares of the specialty pharmaceutical company’s stock worth $283,000 after buying an additional 200 shares in the last quarter. Capstone Asset Management Co. increased its position in Valeant Pharmaceuticals International by 1.4% in the third quarter. Capstone Asset Management Co. now owns 26,408 shares of the specialty pharmaceutical company’s stock worth $648,000 after buying an additional 360 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 402 shares in the last quarter. Breton Hill Capital Ltd. increased its position in Valeant Pharmaceuticals International by 3.7% in the second quarter. Breton Hill Capital Ltd. now owns 17,379 shares of the specialty pharmaceutical company’s stock worth $350,000 after buying an additional 627 shares in the last quarter. Finally, Seven Bridges Advisors LLC increased its position in Valeant Pharmaceuticals International by 2.2% in the second quarter. Seven Bridges Advisors LLC now owns 41,393 shares of the specialty pharmaceutical company’s stock worth $833,000 after buying an additional 890 shares in the last quarter. 67.13% of the stock is owned by institutional investors.

Valeant Pharmaceuticals International Company Profile

Related posts

Leave a Comment